Penumbra, Inc. announced a 15.6% revenue increase to $410.1 million for Q3 2026, driven by strong growth in thrombectomy and embolization products. Net income was $42.3 million, slightly down from the previous year, with a gross profit margin of 68.3%. The company is currently pending acquisition by Boston Scientific and will not provide full-year guidance or hold a conference call. This growth highlights Penumbra's expanding market presence in medical devices for blood clot removal.
Boston Scientific Corporation (BSX) trades at USD 42.68 on Pluang as of Oct 30, 2026 03:12 WIB, showing a modest 0.59% increase in one day. The stock's current market cap stands at $61.49 billion, with a high trading volume of nearly 70 million shares. This trading activity occurs while Penumbra, Inc. reports strong revenue growth and awaits acquisition by Boston Scientific, linking the companies in the medical device sector.
